Trajenta 5mg, also known as linagliptin, is an oral medication used to manage blood sugar levels in individuals with type 2 diabetes. It belongs to the class of dipeptidyl peptidase-4 (DPP-4) inhibitors. Trajenta works by inhibiting the DPP-4 enzyme, which typically breaks down incretin hormones. By blocking this enzyme, Trajenta increases the levels of incretins, specifically GLP-1 and GIP. Elevated incretin levels stimulate insulin release and inhibit glucagon secretion, leading to improved glucose control. Additionally, Trajenta helps regulate blood sugar without causing significant fluctuations, offering a targeted approach to managing diabetes.
